Journal
CANCER INVESTIGATION
Volume 35, Issue 10, Pages 639-646Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357907.2017.1405015
Keywords
Breast cancer; 21-Gene recurrence score; Cancer stem cells; Recurrence risk
Categories
Funding
- National Natural Science Foundation for Young Scientists of China [81602597, 81402506]
- National Natural Science Foundation of China [81272418]
- Natural Science Foundation of Shaanxi Province [2016JM8007]
Ask authors/readers for more resources
To determine the most suitable strategy in treating patients with invasive breast cancer from Northwest China. Lower recurrence score (RS) correlated with lower recurrence ratio. Patients having a medium-high 21-gene RS who received adjuvant therapy presented lower recurrence risk. Younger patients having RS results (>= 31) tended to accept adjuvant therapy more often, however, those having intermediate RS results were inclined to wait and did not receive chemotherapy. These results suggested that RS-based precision medicine will allow individualized diagnosis and treatment, resulting in better outcomes and preserved medical resources.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available